Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1029-1039

  Komatsu, Seiichiro ^a   Miyazawa, Keisuke ^a   Moriya, Shota ^a   Takase, Akiko ^a   Naito, Munekazu ^a   Inazu, Masato ^a   Kohno, Norio ^a   Itoh, Masahiro ^a   Tomoda, Akio ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Autophagy; Bortezomib; Breast cancer; CHOP; Clarithromycin; ER stress

Indexed keywords

BORTEZOMIB; CLARITHROMYCIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEIN P62; SMALL INTERFERING RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; DRUG POTENTIATION; EMBRYO; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BORONIC ACIDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLARITHROMYCIN; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION; HUMANS; PYRAZINES; TRANSCRIPTION FACTOR CHOP;

EID: 84858683912     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1317     Document Type: Article

References (53)

1. Burstein HJ: Novel agents and future directions for refractory breast cancer. Semin Oncol 38 (Suppl. 2): S17-S24, 2011.
2. Higgins MJ and Stearns V: Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62: 281-293, 2011.
3. Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition. Int J Oncol 38: 1197-1217, 2011.
4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ and 10th St. Gallen conference: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144, 2007. (Pubitemid 47244357)
5. Laubach J, Richardson P and Anderson K: Multiple myeloma. Annu Rev Med 62: 249-264, 2011.
6. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916, 2006. (Pubitemid 43882644)
7. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM and Voll RE: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792, 2007. (Pubitemid 46383406)
8. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC and Koumenis C: Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68: 9323-9330, 2008.
9. Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T, Che XF, Naito M, Itoh M and Tomoda A: Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 38: 643-654, 2011.
10. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y and Ueda R: Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512, 2010.
11. Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007. (Pubitemid 46985379)
12. Herr I and Debatin K-M: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2613, 2001.
13. Verfaillie T, Salazar M, Velasco G and Agostinis P: Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010: 1-19, 2010.
14. Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M and Sotiriou C: Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 5: 3042-3051, 2006. (Pubitemid 46092045)
15. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D and Harris AL: The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 69: 4415-4423, 2009.
16. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN and Schoenlein PV: Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy 6: 19-35, 2010.
17. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25: 733-737, 2007. (Pubitemid 350223168)
18. Ishii Y, Papa L, Bahadur U, Yue Z, Aguirre-Ghiso J, Shioda T, Waxman S and Germain D: Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clin Cancer Res 17: 2292-2300, 2011.
19. Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S and Lian JB: A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by down-regulating metastatic genes. Clin Cancer Res 16: 4978-4989, 2010.
20. Mizushima N and Levine B: Autophagy in mammalian development and differentiation. Nat Cell Biol 12: 823-830, 2010.
21. Janku F, McConkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528-539, 2011.
22. Korolchuk VI, Menzies FM and Rubinsztein DC: Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584: 1393-1398, 2010.
23. Kirkin V, McEwan DG, Novak I and Dikic I: A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269, 2009.
24. Mizushima N and Yoshimori T: How to interpret LC3 immuno-blotting. Autophagy 3: 542-545, 2007.
25. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 123: 33-42, 1998. (Pubitemid 28223394)
26. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H and Hata H: Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 37: 815-820, 2010.
27. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK and Niesvizky R: Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 85: 664-669, 2010.
28. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S and Coleman M: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/ dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111: 1101-1109, 2008. (Pubitemid 351213388)
29. Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M and Ferreri AJ: Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 50: 226-229, 2010.
30. Ohe M and Hashino S: Successful treatment with clarithromycin for mixed phenotype acute leukemia, T/myeloid, NOS (in Japanese). Rinsho Ketsueki 51: 297-299, 2010.
31. Mikasa K, Sawaki M, Kita E, Hamada K, Teramoto S, Sakamoto M, Maeda K, Konishi M and Narita N: Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 43: 288-296, 1997. (Pubitemid 27230874)
32. Wada T, Sata M, Sato J, Tokairin Y, Machiya J, Hirama N, Arao T, Inoue S, Takabatake N, Shibata Y and Kubota I: Clarithromycin suppresses invasiveness of human lung adenocarcinoma cells. Chemotherapy 53: 77-84, 2007. (Pubitemid 46377214)
33. Yatsunami J, Fukuno Y, Nagata M, Tsuruta N, Aoki S, Tominaga M, Kawashima M, Taniguchi S and Hayashi S: Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett 147: 17-24, 1999.
34. Hamada K, Kita E, Sawaki M, Mikasa K and Narita N: Antitumor effect of erythromycin in mice. Chemotherapy 41: 59-69, 1995. (Pubitemid 24375194)
35. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N and Kuipers EJ: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772-781, 2007. (Pubitemid 46854190)
36. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H and Hibi T: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 24: 3723-3730, 2004. (Pubitemid 40476069)
37. Ohtomo T, Miyazawa K, Naito M, Moriya S, Kuroda M, Itoh M and Tomoda A: Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation. Biochem Biophys Res Commun 391: 310-315, 2010.
38. Moriya S, Miyazawa K, Kawaguchi T, Che XF and Tomoda A: Involvement of endoplasmic reticulum stress-mediated CHOP (GADD153) induction in the cytotoxicity of 2-aminophenoxazine-3-one in cancer cells. Int J Oncol 39: 981-988, 2011.
39. Tabas I and Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190, 2011.
40. Hoang B, Benavides A, Shi Y, Frost P and Lichtenstein A: Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther 8: 1974-1984, 2009.
41. Nishida Y, Arakawa S, Fujitani K, Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y and Shimizu S: Discovery of Atg5/Atg7-independent alternative macroautophagy. Nature 461: 654-658, 2009.
42. Shimizu S, Arakawa S and Nishida Y: Autophagy takes an alternative pathway. Autophagy 6: 290-291, 2010.
43. Belloni D, Veschini L, Foglieni C, Dell'Antonio G, Caligaris-Cappio F, Ferrarini M and Ferrero E: Bortezomib induces autophagic death in proliferating human endothelial cells. Exp Cell Res 316: 1010-1018, 2010.
44. Zhu K, Dunner K Jr and McConkey DJ: Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29: 451-462, 2010.
45. Rzymski T, Milani M, Singleton DC and Harris AL: Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8: 3838-3847, 2009.
46. Rzymski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I and Harris AL: Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29: 4424-4435, 2010.
47. Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C, Torres S, García S, Nowak J, Fimia GM, Piacentini M, Cecconi F, Pandolfi PP, González-Feria L, Iovanna JL, Guzmán M, Boya P and Velasco G: Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 119: 1359-1372, 2009.
48. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL and Anderson KC: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567-8572, 2005. (Pubitemid 40862776)
49. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, Taylor JP, Cuervo AM and Yao TP: HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29: 969-980, 2010.
50. Iwamoto T, Ishibashi M, Fujieda A, Masuya M, Katayama N and Okuda M: Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy 30: 661-665, 2010.
51. Suzuki A, Iida I, Hirota M, Akimoto M, Higuchi S, Suwa T, Tani M, Ishizaki T and Chiba K: CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab Pharmacokinet 18: 104-113, 2003.
52. Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD and Johansen T: p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285: 22576-22591, 2010.
53. Thompson HG, Harris JW, Wold BJ, Lin F and Brody JP: p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 22: 2322-2333, 2003. (Pubitemid 36566787)